

# Munich Cancer Registry



- ▶ Incidence and Mortality
- ▶ Selection Matrix
- ▶ Homepage
- ▶ *Deutsch*

## ICD-10 C66: Ureteral cancer

### Survival

Year of diagnosis	1988-1997	1998-2019
Patients	94	764
Diseases	94	775
Cases evaluated	64	334
Creation date	01/27/2021	
Database export	01/07/2021	
Population	4.92 m	




Munich Cancer Registry  
Cancer Registry Bavaria - Upper Bavaria Regional Center  
at Klinikum Grosshadern/IBE  
Marchioninstr. 15  
Munich, 81377  
Germany

<https://www.tumorregister-muenchen.de/en>

[https://www.tumorregister-muenchen.de/en/facts/surv/sC66\\_\\_E-ICD-10-C66-Ureteral-cancer-survival.pdf](https://www.tumorregister-muenchen.de/en/facts/surv/sC66__E-ICD-10-C66-Ureteral-cancer-survival.pdf)

**Index of figures and tables**

Fig./Tbl.		Page
1a	Relative survival by period of diagnosis (chart)	3
1b	Survival by period of diagnosis (table)	3
2a	Survival by sex (chart)	4
2b	Survival by sex (table)	4
3a	Relative survival by age category (chart)	5
3b	Survival by age category (table)	5
4a	Relative survival by UICC (chart)	6
4b	Survival by UICC (table)	6
4c	Relative survival by TNM staging (chart)	7
4d	Survival by TNM staging (table)	7
5a	Time to first progression (chart)	8
5b	Time to first progression (table)	8
5c	Observed post-progression survival (chart)	10
5d	Observed post-progression survival (table)	10




**Figure 1a.** Relative survival of patients with ureteral cancer by period of diagnosis. Included in the evaluation are 392 cases diagnosed between 1988 and 2019.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 2000 to 2016, and are represented by colored diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided population-based statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

Years	Period of diagnosis					
	1988-1997 n=64		1998-2006 n=121		2007+ n=207	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0
1	81.0	83.1	83.8	87.1	82.1	85.2
2	69.6	74.0	70.1	76.1	63.9	68.8
3	58.1	63.9	62.4	70.8	56.0	62.7
4	49.8	57.3	55.5	66.0	47.6	55.7
5	48.1	55.8	51.1	62.8	42.1	51.2
6	39.8	48.2	45.8	59.1	39.0	49.6
7	36.4	46.5	41.4	55.7	34.8	46.1
8	34.6	45.6	38.8	54.4	32.8	45.3
9			36.2	52.1		
10			31.7	47.9		
Median	4.0		5.2		3.6	


**Table 1b.** Observed (obs.) and relative (rel.) survival of patients with ureteral cancer by period of diagnosis for period 1988-2019 (N=392).



**Figure 2a.** Survival of patients with ureteral cancer by sex. Included in the evaluation are 328 cases diagnosed between 1998 and 2019.

Years	Sex			
	Male n=191		Female n=137	
	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	86.5	90.0	77.4	80.2
2	70.6	76.5	60.4	64.8
3	60.9	69.0	55.3	61.5
4	51.7	61.7	49.7	57.5
5	45.9	56.9	45.9	54.9
6	41.2	53.6	42.9	52.8
7	38.3	52.3	36.5	47.4
8	36.7	52.1	33.1	45.1
9	35.0	51.1	29.5	41.2
10	33.2	50.5		
Median	4.3		3.9	


**Table 2b.** Observed (obs.) and relative (rel.) survival of patients with ureteral cancer by sex for period 1998-2019 (N=328).



**Figure 3a.** Relative survival of patients with ureteral cancer by age category. Included in the evaluation are 328 cases diagnosed between 1998 and 2019.

Years	Age category			
	0-69 yrs n=115		70+ yrs n=213	
	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	89.4	89.5	79.1	83.7
2	73.1	74.5	62.7	70.1
3	67.1	69.0	53.9	64.2
4	59.7	62.2	45.9	58.6
5	53.4	56.9	41.7	56.5
6	51.2	55.0	36.6	53.2
7	45.7	50.3	33.0	51.8
8	42.4	47.4	31.3	53.0
9	39.9	44.8	28.7	51.6
10	37.2	43.1	25.9	50.3
Median	6.6		3.5	


**Table 3b.** Observed (obs.) and relative (rel.) survival of patients with ureteral cancer by age category for period 1998-2019 (N=328).



**Figure 4a.** Relative survival of patients with ureteral cancer by UICC. For 310 of 328 cases diagnosed between 1998 and 2019 valid data could be obtained for this item. For a total of 309 cases an evaluable classification was established. The grey line represents the subgroup of 19 patients with missing values regarding UICC (5.8 % of 328 patients, the percent values of all other categories are related to n=309). Subgroups with sample size <20 are omitted from the chart.

Years	UICC							
	I n=78		II n=75		III n=102		IV n=48	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	92.1	95.5	93.1	96.4	82.6	85.1	63.8	65.2
2	88.0	95.6	79.0	84.7	63.8	68.6		
3	83.5	94.5	68.5	75.8	55.3	62.7		
4	78.9	93.1	59.2	68.4	41.5	49.8		
5	72.7	89.1	52.9	63.3	36.2	44.4		
Median	10.4		5.9		3.3		1.5	

**Table 4b.** Observed (obs.) and relative (rel.) survival of patients with ureteral cancer by UICC for period 1998-2019 (N=309).




**Figure 4c.** Relative survival of patients with ureteral cancer by TNM staging. For 310 of 328 cases diagnosed between 1998 and 2019 valid data could be obtained for this item. For a total of 299 cases an evaluable classification was established. The accumulated percentage exceeds the 100 % value because patients are potentially considered in more than one subgroup. The grey line represents the subgroup of 29 patients with missing values regarding TNM staging (8.8 % of 328 patients, the percent values of all other categories are related to n=299).

Years	TNM staging													
	T1 n=80		T2 n=77		T3 n=128		N0 n=147		NX n=78		M0 n=72		MX n=100	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	92.3	95.7	93.3	96.6	82.9	85.8	90.7	93.6	89.5	92.7	89.9	91.7	88.7	92.6
2	86.9	94.3	78.2	83.8	58.0	62.3	76.0	81.0	78.6	86.0	69.2	74.0	80.4	87.3
3	82.6	93.2	67.8	74.9	49.4	55.5	70.3	76.9	68.8	80.4	61.3	67.1	70.1	79.8
4	78.2	91.9	58.6	67.6	37.3	44.2	62.0	70.6	60.2	75.0	50.3	57.3	64.9	77.5
5	72.1	88.0	52.4	62.6	32.0	38.8	57.8	67.3	49.9	65.1	43.9	51.4	58.6	72.3
Median	10.3		5.9		2.9		6.2		4.9		4.3		6.3	

TNM staging		
<i>cont'd</i> NA/NOS n=29		
Years	obs. %	rel. %
0	100.0	100.0
Median		

**Table 4d.** Observed (obs.) and relative (rel.) survival of patients with ureteral cancer by TNM staging for period 1998-2019 (N=299).




**Figure 5a.** Time to first progression of 326 patients with ureteral cancer diagnosed between 1998 and 2019 (in solid cancers M0 only) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

	Type of progression							
	Any type (CI)	Any type (1-KM)	Distant metastasis (CI)	Distant metast. (1-KM)	Locoreg. relapse (CI)	Locoreg. rel. (1-KM)	NOS (CI)	
N	310	310	310	310	326	326	326	
Events	130	130	62	62	53	53	44	
compet.	71		120		158		153	
Years	%	%	%	%	%	%	%	%
0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
1	26.2	26.8	9.3	10.1	9.6	10.9	9.8	
2	36.7	38.0	16.0	17.9	14.6	17.4	12.1	
3	39.2	40.9	17.8	20.3	14.9	17.8	12.8	
4	41.6	43.8	20.2	23.7	16.0	19.6	13.6	
5	43.2	45.9	20.2	23.7	17.1	21.8	13.9	
6	44.1	47.2	20.2	23.7	17.6	22.7	14.4	
7	44.1	47.2	21.1	25.3	17.6	22.7	14.4	
8	44.1	47.2	21.1	25.3	17.6	22.7	14.4	
9	44.6	48.2	21.6	26.4	17.6	22.7	14.4	
10	45.2	49.3	22.2	27.6	17.6	22.7	14.4	



Type of progression	
<i>cont'd</i>	NOS (1-KM)
N	326
Events	44
compet.	
Years	%
0	0.0
1	10.3
2	13.1
3	14.1
4	15.4
5	16.1
6	16.9
7	16.9
8	16.9
9	16.9
10	16.9

**Table 5b.** Time to first progression of patients with ureteral cancer for period 1998-2019 (N=326), also showing the total of progression events (Events) and of deaths as competing risk (compet.).



**Figure 5c.** Observed post-progression survival of 109 patients with ureteral cancer diagnosed between 1998 and 2019. These 109 patients with documented progression events during their course of disease represent 33.4 % of the totally 326 evaluated cases (incl. M1, n=16, 4.9 %). Patients with cancer relapse documented via death certificates only were excluded (n=38, 11.7 %). Multiple progression types on different sites are included in the evaluation even when not occurring synchronously. The NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement “not specified” is the only information in registries regarding relapse of the disease. The category “Any type” denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100 % value because patients are potentially considered in more than one subgroup.

Years	Type of progression			
	Any type n=109 %	Distant metastasis n=59 %	Locoregional relapse n=53 %	NOS n=22 %
0	100.0	100.0	100.0	100.0
1	62.9	43.9	64.2	
2	35.3			
3	27.8			
4	23.4			

**Table 5d.** Observed post-progression survival of patients with ureteral cancer for period 1998-2019 (N=109).

## Shortcuts

MCR	Munich Cancer Registry, Germany	
NCI	National Cancer Institute, USA	
SEER	Surveillance, Epidemiology, and End Results, USA	
UICC	Union for International Cancer Control, Geneva	
DCO	Death certificate only	Death certificate provides the only notification to the registry.
NA	Not available	
NOS	Not otherwise specified	
OS	Overall/Observed survival	Overall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any cause
RS	Relative survival	Survival compared to “general population”, ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival
AS	Assembled survival	Assembled chart of observed, expected, relative survival
CS	Conditional survival	Survival probability under the condition of surviving a given period of time
TTP	Time to progression	Time to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression
1-KM		1 minus Kaplan-Meier estimator ("inverse" Kaplan-Meier estimator)
CI		Cumulative incidence Death as competing risk (according to Kalbfleisch und Prentice)
PPS	Post-progression survival	Survival since first progression / relapse (Kaplan-Meier estimate) Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression Event: death from any cause

## Recommended Citation

Munich Cancer Registry. Survival ICD-10 C66: Ureteral cancer [Internet]. 2021 [updated 2021 Jan 27; cited 2021 Mar 1]. Available from: [https://www.tumorregister-muenchen.de/en/facts/surv/sC66\\_\\_E-ICD-10-C66-Ureteral-cancer-survival.pdf](https://www.tumorregister-muenchen.de/en/facts/surv/sC66__E-ICD-10-C66-Ureteral-cancer-survival.pdf)

## Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

## Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.